Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis.

Frontiers in medicine·2026
Same author

APOE4 accelerates menopause-associated brain metabolic shift and disrupts bioenergetic adaptation.

Frontiers in aging neuroscience·2026
Same author

Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment duration.

Frontiers in aging neuroscience·2026
Same author

Addition of humanized APP to humanized <i>APOE</i> mouse model reduces brain size and increases the ratio of cortical representation.

bioRxiv : the preprint server for biology·2026
Same author

Meta analysis of glucose metabolism across Alzheimer's, Parkinson's and ALS Reveals emergence of adaptive brain glucometabolic responses and associated neurological functional profiles.

medRxiv : the preprint server for health sciences·2026
Same author

Premenopausal bilateral oophorectomy leads to steeper declines in gray matter volume and alterations in perfusion and brain bioenergetics.

Scientific reports·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Helena Cortes-Flores1, Georgina Torrandell-Haro1, Roberta Diaz Brinton1

  • 1University of Arizona, Tucson, AZ, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括

抗炎疗法 (aIT) 显著降低了阿尔茨海默病 (AD) 风险,特别是在长期使用和特定药物类别 (如COX抑制剂) 时. 年龄和治疗持续时间是这种神经炎症相关益处的关键因素.

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 老年学是一门学科.

背景情况:

  • 炎症是神经退行性疾病 (如阿尔茨海默氏症) 的关键因素,即使在早期阶段,炎症过程也很明显.
  • 抗炎治疗 (aIT) 在减轻AD风险方面的确切作用仍然是一个需要进一步研究的领域.
  • 这项研究旨在评估aIT对AD发病率的影响,并描述患者对这些治疗的反应.

研究的目的:

  • 评估抗炎疗法 (aIT) 对阿尔茨海默氏病 (AD) 发病率的影响.
  • 为了识别和描述患有AD的患者子组 (非响应者) 与那些在aIT暴露后没有 (响应者).
  • 探索影响aIT和AD风险之间关系的因素,包括药物类别,治疗持续时间和患者人口统计数据.

主要方法:

  • 追溯分析涉及60岁及以上患者的保险索赔数据集.
  • 包括口服皮质类固醇,非选择性COX抑制剂和选择性COX-2抑制剂在研究中.
  • 在225,742名患者的队列中,应用与年龄,性别,查尔森并发症指数 (CCI) 和其他并发症相匹配的倾向性得分与对照者的应用.

主要成果:

  • 抗炎治疗 (aIT) 的使用与AD诊断风险显著降低有关 (RR:0.35 [0.33-0.37],P<.001).

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451
  • 风险降低在使用IT至少一年时更为明显,而COX抑制剂显示出比皮质类固醇更高的疗效.
  • 75-79岁的患者和治疗时间较长 (≥6年) 的患者经历了最显著的风险降低,不论性别.
  • 结论:

    • 这项研究提供了证据,支持抗炎治疗 (aIT) 与阿尔茨海默病 (AD) 风险降低之间的关联.
    • 患者的年龄,aIT暴露的持续时间和特定的药物类别 (例如,COX抑制剂) 是降低AD风险的关键决定因素.
    • 这些发现为开发针对神经炎症的未来干预措施提供了宝贵的见解,以预防AD.